

Clinical factors to predict a poor prognosis and refractory disease in patients with polymyositis and dermatomyositis associated with interstitial lung disease

Sirs,

Interstitial lung disease (ILD) is a serious complication and a poor prognostic factor in patients with polymyositis (PM) and dermatomyositis (DM) (1, 2). Some patients show progressive ILD that is often refractory to corticosteroid (CS) treatment, resulting in a fatal outcome (3–5). Although immunosuppressive drugs, including cyclosporine A (CYA), intravenous cyclophosphamide (IVCY) and methotrexate (MTX) has been shown to be effective (4–8), these were effective when they were started early in the course of ILD (4, 6). Therefore, it is important to predict a poor prognosis and poor response to CS at the initial presentation. We retrospectively investigated the clinical factors, collected at diagnosis, which are associated with a poor prognosis and refractory disease in patients with PM/DM associated with ILD. This study was approved by the ethics committee.

From 2001 to 2005, 61 idiopathic PM/DM patients with ILD, 15 men and 46 women with a mean (\pm SD) age of 53.6 \pm 1.8 years, were analyzed. They consisted of 25 PM patients, 19 classic DM patients, and 17 clinically amyopathic dermatomyositis (CADM) patients. The median duration of follow-up was 35 months (0.1–78 months). Patients with cancer-associated myositis and overlap syndrome were excluded. The diagnosis of PM/DM was based on Bohan and Peter's criteria (9) except for CADM, which was based on the Gerami's definition. (10). All patients were treated with CS (maximum dose of 25 to 100 mg/d). Immunosuppressive/immunomodulating drugs were given to 34 (56%) patients (CYA: 28, IVCY: 5, tacrolimus: 5, azathioprine: 5, MTX: 2, IVIG: 1). Eleven patients (4 PM, 3 classic DM, and 4 CADM) died (fatal group). Among 50 patients, whose ILD remitted or improved, eight (2 classic DM and 6 CADM) were given two immunosuppressive drugs (refractory group), and 42 patients (21 PM, 14 classic DM, and 7 CADM) were treated with CS with or without one immunosuppressive drug (responsive group).

The clinical factors were analysed using a Cox proportional hazards model, comparing fatal and refractory groups with responsive group. On univariate analysis, CADM, skin ulcer, LDH/CK ratio >1, negative anti-Jo-1 antibody, PaO₂/FiO₂ ratio <400, and chest x-ray score (0 = no lesion; 1 = lesions limited in the bottom of the lung; 2 = lesions limited to the lower half of the lung; 3 = lesions in the lower and upper areas of the lung; and 4 = diffuse lesions) >2 were associated with fatal or refractory disease. Because the PaO₂/FiO₂ ratio and the chest x-ray score




Fig. 1. Evaluation of the clinical scoring system. **A.** Comparison of the scores between fatal/refractory patients and responsive patients. The scores of the two groups are significantly different ($p<0.0001$). **B.** Survival curves defined by the time to the introduction of the second immunosuppressive/immunomodulating agent or death by current score. Patients were divided into three groups according to the score (score 0, $n=23$; score 1, $n=27$; score 2, $n=9$). The survival curves are significantly different ($p<0.0001$ and $p=0.047$ for trend). **C.** Survival curves showing the time to death by current score ($p<0.0024$ and $p=0.208$ for trend).

represent the severity of ILD, these two items were combined as PaO₂/FiO₂ <400 OR chest x-ray score >2. On multivariate analysis, PaO₂/FiO₂ <400 OR chest x-ray score >2 (HR 5.09, 95%CI 1.69–15.39, $p=0.004$) and LDH/CK >1 (HR 3.71, 95%CI 1.17–11.72, $p=0.026$) were significant independent factors. Based on these results, we propose a preliminary simple score, the number of positive risk factors to predict a poor prognosis and refractory disease. In 59 patients, who had an adequate data set, the scores were significantly different between fatal/refractory cases and responsive cases (Fig. 1A, $p<0.0001$). The sensitivity and specificity of the cut-off ≥ 1 were 95% and 55%, respectively. The survival curves of the endpoint, the time to the introduction of second immunosuppressive/immunomodulating agents or death correlated with the score ($p=0.0007$, $p=0.047$ for trend, Fig. 1B). Survival curves that indicate the time to death also showed a similar trend, although it was not significant ($p=0.0024$, $p=0.208$ for trend, Fig. 1C).

The present study showed that the preliminary prediction is valid and may serve as a guide to deciding the initial therapeutic strategy in the treatment of PM/DM associated with ILD. It is necessary to validate this scoring system using a larger cohort.

Y. TADA¹, MD, PhD
E. SUEMATSU², MD, PhD
A. UEDA³, MD, PhD
S. NAGANO⁴, MD, PhD
T. SAWABE⁵, MD, PhD
H. NISHIZAKA⁶, MD, PhD
T. HORIUCHI⁷, MD, PhD

¹Department of Rheumatology, Faculty of Medicine, Saga University, Saga;

²Department of Internal Medicine and Rheumatology, Clinical Research Center, National Hospital Organization Kyushu Medical Center, Fukuoka; ³Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Miyazaki; ⁴Department of Rheumatology, Oita Red Cross Hospital, Oita; ⁵Department of Rheumatology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima; ⁶Department of Internal

Medicine, Kitakyushu Municipal Medical Center, Kitakyushu; ⁷Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Address correspondence to: Yoshifumi Tada, Department of Rheumatology, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.

E-mail: tada@cc.saga-u.ac.jp

Competing interests: none declared.

References

- KANG EH, LEE EB, SHIN KC *et al.*: Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. *Rheumatology* 2005; 44: 1282–6.
- YE S, CHEN X, LU X *et al.*: Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. *Clin Rheumatol* 2007; 26: 1647–54.
- SONTHEIMER RD, MIYAGAWA S: Potentially fatal interstitial lung disease can occur in clinically amyopathic dermatomyositis. *J Am Acad Dermatol* 2003; 48: 797–8.
- NAWATA Y, KURASAWA K, TAKABAYASHI K *et al.*: Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporine. *J Rheumatol* 1999; 26: 1527–33.
- KAMEDA H, NAGASAWA H, OGAWA H *et al.*: Combination therapy with corticosteroids, cyclosporine A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. *J Rheumatol* 2005; 32: 1719–26.
- YAMASAKI Y, YAMADA H, YAMASAKI M *et al.*: Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. *Rheumatology* 2007; 46: 124–30.
- KOTANI T, MAKINO S, TAKEUCHI T *et al.*: Early intervention with corticosteroids and cyclosporine A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. *J Rheumatol* 2008; 35: 254–9.
- FENDLER C, BRAUN J: Use of methotrexate in inflammatory myopathies. *Clin Exp Rheumatol* 2010; 28 (Suppl. 61): S164–7.
- BOHAN A, PETER JB: Polymyositis and dermatomyositis (first of 2 parts). *N Engl J Med* 1975; 292: 344–7.
- GERAMI P, SCOPE JM, McDONALD L, WALLING HW, SONTHEIMER RD: A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): A missing link within the spectrum of the idiopathic inflammatory myopathies. *J Am Acad Dermatol* 2006; 54: 597–613.